ライフサイエンスコーパス: teicoplanin

1 hibit glycolytic switching after exposure to teicoplanin.

2 observed in combination with vancomycin and teicoplanin.

3 ns that achieve site-selective alteration of teicoplanin.

4 imics the biological mechanism of action for teicoplanin.

5 in, amoxicillin/clavulanate, vancomycin, and teicoplanin.

6 le to linezolid, daptomycin, vancomycin, and teicoplanin.

7 ated derivatives (GtfC, D) of vancomycin and teicoplanin.

8 keratoplasty received ciprofloxacin 0.3% or teicoplanin 1%.

9 Nine linezolid trials (vancomycin [7]; teicoplanin [2]) were included (n = 2329).

10 experimental study, we compared intravenous teicoplanin (3 mg/kg, n = 12), a cocktail of four phages

11 crog/ml), amphotericin B (10 microg/ml), and teicoplanin (4 microg/ml) (CAT medium; Oxoid Limited, Ha

12 ne than the two other sugar rings present in teicoplanin (9.3 and 20.3 A, respectively).

13 tained for tetracycline (99.5% [99.1-99.7]), teicoplanin (98.9% [98.4-99.3]), and high-level resistan

14 dentified were glycopeptide antibiotics, but teicoplanin, a membrane-anchored glycopeptide, failed to

15 is study, we used the macrocyclic antibiotic teicoplanin, a molecule consisting of an aglycone peptid

16 The hydrodynamic properties of teicoplanin A2 (M(1) = 1880 g/mol) were examined in phos

17 In the concentration range, 0-10 mg/mL teicoplanin A2 was found to self-associate plateauing >

18 Teicoplanin A2-2 (Tei)/A40926 is the last-line antibioti

19 a site-selective peptide catalyst moiety and teicoplanin A2-2 complex.

20 lective phosphorylation reaction involving a teicoplanin A2-2 derivative.

21 lation of the N-acetylglucosamine sugar in a teicoplanin A2-2 derivative.

22 onstruct was crystallized in the presence of teicoplanin A2-2.

23 s within the complex glycopeptide antibiotic teicoplanin A2-2.

24 7 A, based on the X-ray crystal structure of teicoplanin A2-2.

25 ripeptide precursor to the common vancomycin/teicoplanin ABCD ring system and sequential DE macrocycl

26 tudies leading to the total synthesis of the teicoplanin aglycon are provided.

27 It was found that only teicoplanin aglycon CSP provided sufficient resolution o

28 ) = 60 min(-1)), and an unnatural substrate, teicoplanin aglycone (k(cat) = 20 min(-1)).

29 Using the teicoplanin aglycone and the 3 sulfotransferases found i

30 dy we investigate the first two reactions in teicoplanin aglycone maturation catalyzed by the enzymes

31 in the second dimension ((2)D) (teicoplanin, teicoplanin aglycone, crown ether, and zwitterionic quin

32 enosine 5'-phosphate, and Teg12 bound to the teicoplanin aglycone.

33 r = 0.3 min(-1), for an alternate substrate, teicoplanin aglycone.

34 iological activity of the new phosphorylated teicoplanin analogs and compare the results to the natur

35 five compounds were better separated on the teicoplanin and aglycone CSPs, respectively.

36 ancin however two showed cross-reactivity to teicoplanin and telavancin.

37 Whilst the interaction between teicoplanin and Ti was robust, we found that phosphate r

38 The binding constants for the interaction of teicoplanin and vancomycin with the fluorescent peptide

39 faecium isolate was highly resistant to both teicoplanin and vancomycin, corresponding to the VanA ph

40 scourage attempts at covalently immobilising teicoplanin and/or other glycopeptide antibiotics in the

41 ancomycin, 0.25 microM and 0.25-2 microM for teicoplanin, and 1 microM and 1-8 microM for telavancin.

42 meropenem and teicoplanin, moxifloxacin and teicoplanin, and ciprofloxacin and teicoplanin, gave the

43 , trimethoprim-sulfamethoxazole, vancomycin, teicoplanin, and linezolid.

44 susceptibility panels containing vancomycin, teicoplanin, and six oral antibiotics of potential use i

45 three glycopeptide antibiotics, vancomycin, teicoplanin, and telavancin, as model compounds, we demo

46 tter specificity for ampicillin, vancomycin, teicoplanin, and tetracycline resistance.

47 ing site in the maturation of vancomycin and teicoplanin antibiotic scaffolds, were expressed in Esch

48 The glycopeptides vancomycin and teicoplanin are clinically important antibiotics.

49 Vancomycin and teicoplanin are not associated with more renal dysfuncti

50 alter reaction selectivities, certain bromo-teicoplanins are accessible.

51 MarR family transcriptional regulator of the teicoplanin-associated locus TcaR, DNA-binding protein I

52 For the mixtures of teicoplanin at higher doses (1.25 mg/mL and 12.5 mg/mL),

53 All AAs were derivatized and analyzed on a teicoplanin-based chiral column.

54 -bonded silica, Pirkle-type, vancomycin, and teicoplanin-bonded silica particles were evaluated for r

55 de antibiotics vancomycin, ristocetin A, and teicoplanin can all be used as chiral selectors in capil

56 nd N-protected amino acids on a zwitterionic teicoplanin chiral stationary phase (CSP), prepared on s

57 Although in contrast to teicoplanin ciprofloxacin shows good corneal penetration

58 t sugar forms of both the vancomycin and the teicoplanin class of glycopeptide antibiotics.

59 Teicoplanin combined with meropenem, ciprofloxacin, or m

60 e resulting 2.3 A resolution protein-peptide-teicoplanin complex crystal structure revealed that the

61 In the chemical assay, teicoplanin could not be detected in the cornea or aqueo

62 free energy between the aglycone CSP and the teicoplanin CSP was between 0.3 and 1 kcal/mol for amino

63 no acid compounds were separated only on the teicoplanin CSP.

64 m) of different surface chemistries, namely, teicoplanin, cyclofructan, silica, and quinine, were pac

65 al assignment of the distinct phosphorylated teicoplanin derivatives.

66 ing the HILIC mechanism and cyclodextrin- or teicoplanin-derivatized stationary phases, effective res

67 n of enzymatic tetracyclization of synthetic teicoplanin-derived heptapeptides and furthermore discer

68 e to ampicillin, gentamicin, vancomycin, and teicoplanin developed.

69 resistance detection (GRD) using vancomycin-teicoplanin double-sided gradient test strips on Mueller

70 The complex antibiotic teicoplanin eradicates bacterial infections.

71 We suggest that teicoplanin eye drop formulations should be delivered at

72 onsible for the production of the vancomycin/teicoplanin family of antibiotic natural products.

73 This includes the macrocyclic glycopeptide, teicoplanin, following the discovery, in the 1990's, tha

74 ials that tested linezolid vs. vancomycin or teicoplanin for treatment of nosocomial pneumonia were i

75 ffinity between the glycopeptide antibiotics teicoplanin from Actinoplanes teicomyceticus and vancomy

76 xacin and teicoplanin, and ciprofloxacin and teicoplanin, gave the lowest mean FICs for S. aureus, wi

77 tant Staphylococcus aureus agents, including teicoplanin, had favorable activity, and the strains wit

78 antimicrobial agents, such as vancomycin and teicoplanin, have emerged in the United States and elsew

79 olydopamine and use this platform to capture teicoplanin, however we were unable to avoid the natural

80 nclusions: Phage therapy was as effective as teicoplanin in improving survival and decreasing bacteri

81 ain Results: Treatment with either phages or teicoplanin increased survival from 0% to 58% and 50%, r

82 Teicoplanin is the most distinct of the three and is the

83 The natural glycopeptide antibiotic teicoplanin is used for the treatment of serious Gram-po

84 nsferases (Teg12, -13, and -14) that sulfate teicoplanin-like glycopeptides at three unique sites.

85 linical trials suggest that nitazoxanide and teicoplanin may be alternative options to standard thera

86 ealing that selective chemical alteration of teicoplanin may lead to analogues with attenuated or enh

87 C/CLSI), Mueller-Hinton agar with 5 mg/liter teicoplanin (MHA5T) (European Antimicrobial Resistance S

88 ially positive for 68 isolates (1.6%; all by teicoplanin MIC >/= 8 mug/ml at 24 or 48 h).

89 MICs were > or =4 microg/ml or for which the teicoplanin MICs were > or =8 microg/ml and 24 control s

90 MICs were < or =2 microg/ml or for which the teicoplanin MICs were < or =4 microg/ml to determine the

91 hromosome mec allotyping, and vancomycin and teicoplanin MICs were performed on 821 consecutive MRSA

92 In contrast, there were no increases in teicoplanin MICs.

93 epared in a similar way, one with the native teicoplanin molecule and the other with the aglycone.

94 ng sites for the "capture" of vancomycin and teicoplanin molecules, which may be part of the mechanis

95 s meropenem and ciprofloxacin, meropenem and teicoplanin, moxifloxacin and teicoplanin, and ciproflox

96 993 had agar dilution MICs of vancomycin and teicoplanin of 128 and 4 microg/mL, respectively.

97 g of vancomycin per liter and > or =8 microg teicoplanin per ml or > or =12 microg of teicoplanin per

98 rog teicoplanin per ml or > or =12 microg of teicoplanin per ml.

99 antibiotics (GPAs), including vancomycin and teicoplanin, represent the most important class of anti-

100 ngly, all tested RT106 strains had increased teicoplanin resistance, and a majority displayed collage

101 f at position 261 in the mutant selected for teicoplanin resistance.

102 Both vancomycin- and teicoplanin-resistant laboratory mutants of Staphylococc

103 rties, in particular against vancomycin- and teicoplanin-resistant strains.

104 yses for 16,749 isolates using vancomycin or teicoplanin results to categorize dalbavancin susceptibi

105 aglycone (GtfC and GtfD) or the glucosylated teicoplanin scaffold, 7 (GtfD).

106 Teicoplanin shows relatively poor corneal penetration th

107 rization immunoassay (FPIA) kit in detecting teicoplanin spiked in human blood samples.

108 lanin to Ti we examined whether a commercial teicoplanin stationary phase could kill staphylococci.

109 aa peptide motif that is known to target the teicoplanin structure in a specific manner.

110 n 6 micro g of vancomycin/ml, vancomycin and teicoplanin susceptibility, API 20S assay, and genotypin

111 . aureus (VISA) and vancomycin-resistant and teicoplanin-susceptible (VanB phenotype) E. faecalis wer

112 iral columns in the second dimension ((2)D) (teicoplanin, teicoplanin aglycone, crown ether, and zwit

113 d (i) Etest macromethod using vancomycin and teicoplanin test strips, brain heart infusion (BHI) agar

114 everal agents other than vancomycin, such as teicoplanin, tetracyclines, and trimethoprim/sulfamethox

115 For teicoplanin, the mean (median) concentration in the corn

116 cally relevant glycopeptides, vancomycin and teicoplanin, threatens to undermine the usefulness of th

117 ore contemplating the covalent attachment of teicoplanin to Ti we examined whether a commercial teico

118 pi-vancosamine, to synthesize a novel hybrid teicoplanin/vancomycin glycopeptide.

119 ibility of the enterococci to vancomycin and teicoplanin was determined using an Etest (AB Biodisk, S

120 imilar glycolytic switching is observed with teicoplanin, which did not activate T cells, it is possi

121 last line of defence glycopeptide antibiotic teicoplanin with an ocular mucin model using precision m

122 Importantly teicoplanin works at the level of the bacterial cell wal